Polyethylene glycol 300

Identification

Brand Names
Advanced Eye Relief Redness Instant Relief
Generic Name
Polyethylene glycol 300
DrugBank Accession Number
DB11161
Background

Polyethylene glycol 300 (PEG 300) is a water-miscible polyether with an average molecular weight of 300 g/mol. It is a clear viscous liquid at room temperature with non-volatile, stable properties 1. Polyethylene glycols are widely used in biochemistry, structural biology, and medicine in addition to pharmaceutical and chemical industries. They serve as solubilizers, excipients, lubricants, and chemical reagents. Low molecular weight glycols are observed to exhibit antibacterial properties as well. PEG 300 is found in eye drops as a lubricant to temporarily relieve redness, burning and irritation of the eyes.

Type
Small Molecule
Groups
Approved
Synonyms
  • Macrogol 300
  • PEG 300
  • PEG-6

Pharmacology

Indication

Indicated as a lubricant in over-the-counter ophthalmic solutions to temporarily relieve redness, burning and irritation of the eyes.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

PEGs act as nonionic surfactant to decrease surface tension and condition the stratum corneum, thus enhance the diffusion of other molecules or drugs through the skin 1.

Mechanism of action

Due to their physical properties, PEG acts as a surfactant by coating the eye. It provides lubrication and surface protection in dry eyes.

Absorption

PEGs can be absorbed by the gastrointestinal tract following oral administration with the fraction absorbed being dependent on the molecular weight of the compound 1. It is likely to display minimal absorption through the intact skin, but may penetrate through injured skin with compromised barrier function 1.

Volume of distribution

No pharmacokinetic data available.

Protein binding

No pharmacokinetic data available.

Metabolism

Proportion of absorbed PEGs may be metabolized to lower oligomers, glycolic acid, hydroxyglycolic acids and the diglycolic acids homologs, carbon dioxide that is exhaled, and to a minor extent, oxalic acid 1.

Route of elimination

After oral and intravenous exposure, PEGs are excreted mainly unchanged in the urine and faeces 1.

Half-life

No pharmacokinetic data available.

Clearance

No pharmacokinetic data available.

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Oral LD50 in rat and mouse are 27500 mg/kg and 31000 mg/kg, respectively MSDS. Dermal LD50 is reported to be 20000 mg/kg in rabbit MSDS. PEGs and their derivatives are not known to cause ocular and dermal irritation, and are associated with low acute and chronic toxicities 1.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Advanced Eye Relief/ Redness Instant ReliefPolyethylene glycol 300 (2 mg/1mL) + Naphazoline hydrochloride (0.1 mg/1mL)Solution / dropsOphthalmicBausch & Lomb Incorporated2010-09-13Not applicableUS flag
ALL CLEAR EYE DROPSPolyethylene glycol 300 (0.2 %) + Naphazoline hydrochloride (0.012 %)SolutionOphthalmicBAUSCH & LOMB (SINGAPORE) PRIVATE LIMITED2003-01-16Not applicableSingapore flag
Lubricant and Redness RelieverPolyethylene glycol 300 (2 mg/1mL) + Naphazoline hydrochloride (0.1 mg/1mL)Solution / dropsOphthalmicTARGET Corporation2010-09-132021-08-31US flag
Original Redness RelieverPolyethylene glycol 300 (2 mg/1mL) + Naphazoline hydrochloride (0.1 mg/1mL)Solution / dropsOphthalmicRite Aid2010-09-13Not applicableUS flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
5655G9Y8AQ
CAS number
25322-68-3
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
  1. Fruijtier-Polloth C: Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products. Toxicology. 2005 Oct 15;214(1-2):1-38. doi: 10.1016/j.tox.2005.06.001. [Article]
PubChem Substance
347911138
RxNav
8513
MSDS
Download (47.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionOphthalmic0.012 %
Solution / dropsOphthalmic
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)-11MSDS
water solubilitySolubleMSDS
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at December 03, 2015 16:51 / Updated at January 07, 2021 03:13